235 related articles for article (PubMed ID: 9862428)
1. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments.
El-Agnaf OM; Jakes R; Curran MD; Middleton D; Ingenito R; Bianchi E; Pessi A; Neill D; Wallace A
FEBS Lett; 1998 Nov; 440(1-2):71-5. PubMed ID: 9862428
[TBL] [Abstract][Full Text] [Related]
2. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease.
El-Agnaf OM; Jakes R; Curran MD; Wallace A
FEBS Lett; 1998 Nov; 440(1-2):67-70. PubMed ID: 9862427
[TBL] [Abstract][Full Text] [Related]
3. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Conway KA; Harper JD; Lansbury PT
Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
[TBL] [Abstract][Full Text] [Related]
4. Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity.
Bodles AM; Guthrie DJ; Greer B; Irvine GB
J Neurochem; 2001 Jul; 78(2):384-95. PubMed ID: 11461974
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils.
Bodles AM; Guthrie DJ; Harriott P; Campbell P; Irvine GB
Eur J Biochem; 2000 Apr; 267(8):2186-94. PubMed ID: 10759841
[TBL] [Abstract][Full Text] [Related]
6. Initiation and synergistic fibrillization of tau and alpha-synuclein.
Giasson BI; Forman MS; Higuchi M; Golbe LI; Graves CL; Kotzbauer PT; Trojanowski JQ; Lee VM
Science; 2003 Apr; 300(5619):636-40. PubMed ID: 12714745
[TBL] [Abstract][Full Text] [Related]
7. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
[TBL] [Abstract][Full Text] [Related]
8. Structural transformation and aggregation of human alpha-synuclein in trifluoroethanol: non-amyloid component sequence is essential and beta-sheet formation is prerequisite to aggregation.
Li HT; Du HN; Tang L; Hu J; Hu HY
Biopolymers; 2002 Aug; 64(4):221-6. PubMed ID: 12115139
[TBL] [Abstract][Full Text] [Related]
9. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
Narhi L; Wood SJ; Steavenson S; Jiang Y; Wu GM; Anafi D; Kaufman SA; Martin F; Sitney K; Denis P; Louis JC; Wypych J; Biere AL; Citron M
J Biol Chem; 1999 Apr; 274(14):9843-6. PubMed ID: 10092675
[TBL] [Abstract][Full Text] [Related]
10. Engineered alpha-synuclein prevents wild type and familial Parkin variant fibril formation.
Sode K; Usuzaka E; Kobayashi N; Ochiai S
Biochem Biophys Res Commun; 2005 Sep; 335(2):432-6. PubMed ID: 16081040
[TBL] [Abstract][Full Text] [Related]
11. Neuropathology of synuclein aggregates.
Duda JE; Lee VM; Trojanowski JQ
J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
[TBL] [Abstract][Full Text] [Related]
12. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
Foguel D; Suarez MC; Ferrão-Gonzales AD; Porto TC; Palmieri L; Einsiedler CM; Andrade LR; Lashuel HA; Lansbury PT; Kelly JW; Silva JL
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9831-6. PubMed ID: 12900507
[TBL] [Abstract][Full Text] [Related]
13. The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation.
Kessler JC; Rochet JC; Lansbury PT
Biochemistry; 2003 Jan; 42(3):672-8. PubMed ID: 12534279
[TBL] [Abstract][Full Text] [Related]
14. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
[TBL] [Abstract][Full Text] [Related]
15. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
[TBL] [Abstract][Full Text] [Related]
16. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
[TBL] [Abstract][Full Text] [Related]
17. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.
Mishizen-Eberz AJ; Guttmann RP; Giasson BI; Day GA; Hodara R; Ischiropoulos H; Lee VM; Trojanowski JQ; Lynch DR
J Neurochem; 2003 Aug; 86(4):836-47. PubMed ID: 12887682
[TBL] [Abstract][Full Text] [Related]
18. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein.
Du HN; Tang L; Luo XY; Li HT; Hu J; Zhou JW; Hu HY
Biochemistry; 2003 Jul; 42(29):8870-8. PubMed ID: 12873148
[TBL] [Abstract][Full Text] [Related]
19. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation.
Kanda S; Bishop JF; Eglitis MA; Yang Y; Mouradian MM
Neuroscience; 2000; 97(2):279-84. PubMed ID: 10799759
[TBL] [Abstract][Full Text] [Related]
20. Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity.
Li W; Lee MK
J Neurochem; 2005 Jun; 93(6):1542-50. PubMed ID: 15935070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]